Please assess the completion status of the following clinical trial:

Trial Title: Study of NMS-1116354 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced/metastatic solid tumors, for which no alternative effective standard therapy is available~2. Maximum of 4 regimens of prior cancer therapy allowed~3. Prior radiotherapy allowed if no more than 25% of BM reserve irradiated~4. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy~5. ECOG performance status (PS) 0 or 1~6. Adult (age \>/= 18 and \</= 80 years) patients~7. Adequate renal, liver and BM reserve~8. Capability to swallow capsules intact~Exclusion Criteria:~1. Current enrollment in another therapeutic clinical trial~2. Known brain metastases~3. Currently active second malignancy~4. Major surgery within 4 weeks prior to treatment~5. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~6. Pregnancy or breast-feeding women~7. Known active infections~8. Gastrointestinal disease or other malabsorption syndromes that would impact on drug absorption~9. Adrenal insufficiency~10. Other severe acute or chronic medical or psychiatric condition that could compromise protocol objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).